WHO ICTRP trial
Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk…
JPRN-UMIN000005662 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000005662 |
|---|---|
| Public title | Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome |
| Scientific title | Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome - Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome |
| Primary sponsor | Department of Hematology, Kinki University School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | low-risk myelodysplastic syndrome |
| Interventions | The dosage is 75mg/m2 of azacitidine by subcutaneous injection or intravenous infusion for 10 minutes once daily for 7 days every four weeks. |
| Registration date | May 30, 2011 |
| Target size | 50 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: